866-997-4948(US-Canada Toll Free)

Atrial Fibrillation-Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Feb 2018

Category :

Pharmaceutical

No. of Pages : 98 Pages

Atrial Fibrillation - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H1 2018, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 4, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Atrial Fibrillation - Overview
Atrial Fibrillation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Atrial Fibrillation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Atrial Fibrillation - Companies Involved in Therapeutics Development
Acesion Pharma Aps
ARCA biopharma Inc
AstraZeneca Plc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Cardiome Pharma Corp
Daiichi Sankyo Co Ltd
Dong-A Socio Holdings Co Ltd
Edge Therapeutics Inc
Gilead Sciences Inc
InCarda Therapeutics Inc
Merck & Co Inc
N-Gene Research Laboratories Inc
Nissan Chemical Industries Ltd
OMEICOS Therapeutics GmbH
The Geneva Biotech Center SA
Verseon Corp
Atrial Fibrillation - Drug Profiles
AFC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGP-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-919373 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-1728515 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bucindolol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budiodarone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-1965 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flecainide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBCA-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heparin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-1832 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIP-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Calcium Activated Potassium Channel for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LGALS3 for Cardiovascular, Respiratory and Genito Urinary System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-1902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-2851 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vernakalant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrial Fibrillation - Dormant Projects
Atrial Fibrillation - Discontinued Products
Atrial Fibrillation - Product Development Milestones
Featured News & Press Releases
Dec 12, 2017: Espero BioPharma Provides Update on Budiodarone
Nov 15, 2017: New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017
Nov 13, 2017: OMEICOS Announces Formation of Inaugural Clinical Advisory Board
Nov 08, 2017: Daiichi Sankyo Announces New Analyses of Once-Daily SAVAYSA (edoxaban) to be Presented at the 2017 American Heart Association Scientific Sessions
Nov 02, 2017: Cardiome Announces Expansion of Global Geographic Footprint for Brinavess
Oct 06, 2017: Daiichi Sankyo to Install Call Center Support System in Japan Utilizing Artificial Intelligence
Sep 14, 2017: G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals
Aug 30, 2017: New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS
Aug 29, 2017: New Sub-analysis Data Highlights the Benefit of LIXIANA (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring
Aug 21, 2017: Daiichi Sankyo Announces Its Clinical Presentations at ESC Congress 2017
Aug 21, 2017: Cardiome Provides U.S. Regulatory Update For BRINAVESS
Jul 17, 2017: CHMP Issues a Positive Opinion for Daiichi Sankyos Once-Daily LIXIANA (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Jun 12, 2017: Cardiome Announces Commercial Launch of BRINAVESS (Vernakalant Hydrochloride) in Canada
Jun 07, 2017: InCarda Therapeutics Announces Positive Clinical Data Supporting Development of Inhaled Flecainide for the Treatment of Symptomatic Acute Events of Paroxysmal Atrial Fibrillation
Jun 07, 2017: OMEICOS Secures Continued BMBF Support with New 1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Atrial Fibrillation, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H1 2018
Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H1 2018
Atrial Fibrillation - Pipeline by AstraZeneca Plc, H1 2018
Atrial Fibrillation - Pipeline by Boston Pharmaceuticals Inc, H1 2018
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Co, H1 2018
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H1 2018
Atrial Fibrillation - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018
Atrial Fibrillation - Pipeline by Edge Therapeutics Inc, H1 2018
Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H1 2018
Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H1 2018
Atrial Fibrillation - Pipeline by Merck & Co Inc, H1 2018
Atrial Fibrillation - Pipeline by N-Gene Research Laboratories Inc, H1 2018
Atrial Fibrillation - Pipeline by Nissan Chemical Industries Ltd, H1 2018
Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H1 2018
Atrial Fibrillation - Pipeline by The Geneva Biotech Center SA, H1 2018
Atrial Fibrillation - Pipeline by Verseon Corp, H1 2018
Atrial Fibrillation - Dormant Projects, H1 2018
Atrial Fibrillation - Dormant Projects, H1 2018 (Contd..1), H1 2018
Atrial Fibrillation - Dormant Projects, H1 2018 (Contd..2), H1 2018
Atrial Fibrillation - Discontinued Products, H1 2018
Atrial Fibrillation - Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures
Number of Products under Development for Atrial Fibrillation, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *